Exelixis, Inc. (NASDAQ:EXEL) Position Boosted by Teacher Retirement System of Texas

Teacher Retirement System of Texas boosted its position in Exelixis, Inc. (NASDAQ:EXEL) by 15.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 76,017 shares of the biotechnology company’s stock after buying an additional 10,264 shares during the quarter. Teacher Retirement System of Texas’ holdings in Exelixis were worth $2,531,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Tri Ri Asset Management Corp bought a new stake in shares of Exelixis in the 3rd quarter valued at approximately $4,396,000. Blue Trust Inc. boosted its holdings in Exelixis by 134.7% in the fourth quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 8,208 shares during the period. Range Financial Group LLC bought a new stake in Exelixis during the fourth quarter valued at $994,000. FMR LLC raised its holdings in shares of Exelixis by 6.1% during the third quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock worth $63,891,000 after purchasing an additional 140,568 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Exelixis by 82.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock worth $52,884,000 after buying an additional 704,786 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on EXEL. Oppenheimer downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $41.00 to $33.00 in a research report on Friday, January 24th. Stifel Nicolaus increased their price target on Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research report on Wednesday, February 12th. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Exelixis in a research report on Thursday, February 13th. Barclays increased their target price on Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Finally, Guggenheim restated a “buy” rating and set a $42.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.59.

Exelixis Stock Down 1.9 %

Shares of EXEL stock opened at $37.01 on Thursday. The stock has a 50-day simple moving average of $35.69 and a 200 day simple moving average of $33.12. The stock has a market capitalization of $10.36 billion, a P/E ratio of 20.91, a P/E/G ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $40.02.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, sell-side analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Insider Buying and Selling at Exelixis

In related news, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the transaction, the executive vice president now directly owns 341,028 shares in the company, valued at $13,231,886.40. The trade was a 2.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bob Oliver sold 18,647 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total value of $694,600.75. Following the sale, the director now directly owns 33,514 shares in the company, valued at $1,248,396.50. This trade represents a 35.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 140,343 shares of company stock valued at $5,177,234. Corporate insiders own 2.85% of the company’s stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.